FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a monoclonal antibody that specifically binds to a pathogenic hyperphosphorylated tau-protein. The application of the specified antibody for the treatment of taupathy and for the treatment of Alzheimer’s disease is also disclosed.
EFFECT: invention has the capability of the effective treatment of diseases associated with a tau-protein.
7 cl, 11 ex, 6 tbl, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
| MONOCLONAL ANTIBODIES TO ALPHA-SYNUCLEIN FOR PREVENTING TAU-PROTEIN AGGREGATION | 2017 |
|
RU2760334C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| ANTIBODIES SPECIFIC TO FLT3 AND THEIR APPLICATIONS | 2018 |
|
RU2758513C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| C3 BINDING AGENTS AND METHODS OF THEIR USE | 2019 |
|
RU2802307C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | 2017 |
|
RU2755503C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | 2018 |
|
RU2820628C2 |
